Bridge Biotherapeutics Announces Initiation of the Phase I Clinical Tr..
◆China Phase I study of BBT-401 had its first subject dosed in Chengdu, China◆The company seeks to accelerate its busine..
Bridge Biotherapeutics Presents Pre-Clinical Data of BBT-176 at the Eu..
◆Pre-clinical data exploring the in vitro and in vivo efficacy of BBT-176 will be disclosed via an ePoster at the ESMO C..
Bridge Biotherapeutics Integrates CDD Vault Collaborative Database Sol..
◆Bridge has been enhancing its research and drug discovery engines by efficiently managing scientific assets on a collab..
Bridge Biotherapeutics Announces the Initiation of Patient Dosing in t..
◆ The Phase IIa, proof of clinical principle study, had its first patient dosed in the USA◆ A new drug formulation is ex..
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechan..
◆ The new proof of mechanism trial in ulcerative colitis had its first patient dosed in New Zealand◆In parallel with the..
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Tria..
Bridge Biotherapeutics Inc., a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced th..
Termination of Bridge Biotherapeutics’s Collaboration and License Agre..
On November 9, 2020, Bridge Biotherapeutics reported to the Korea Stock Exchange that the Company and Boehringer Ingelhe..
Bridge Biotherapeutics Announces Detailed Plans for the Phase 2a Study..
- The data from the low dose cohort confirms the safety and efficacy of BBT-401, Bridge Biotherapeutics’ novel drug cand..